Haemonetics Expects FY24 Revenue Growth Of 4%-7%, And Organic Growth Of 5%-8%; Sees Adjusted EPS Of $3.45-$3.75 Vs. $3.4 Estimate

Benzinga · 05/11/2023 06:11

Adjusted operating margin20 - 21% Adjusted earnings per diluted share$3.45 - $3.75 Free cash flow, before restructuring and restructuring related costs$80M - $100M